NuCana plc Presents Final Phase 2 NuTide Data
Ticker: NCNA · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, biotech, oncology
TL;DR
NuCana dropped final Phase 2 NuTide data on 9/14. Investors watching closely.
AI Summary
NuCana plc announced on September 14, 2024, the presentation of final data from its Phase 2 NuTide study. The study focused on the treatment of patients with biliary tract cancer. The press release was filed as a Form 6-K with the SEC.
Why It Matters
The presentation of final data from a Phase 2 study is crucial for understanding the efficacy and safety of NuCana's treatment, potentially impacting future clinical development and investor outlook.
Risk Assessment
Risk Level: medium — The filing reports on clinical trial data, which inherently carries risks related to study outcomes and future regulatory approvals.
Key Players & Entities
- NuCana plc (company) — Registrant
- NuTide (drug_candidate) — Name of the Phase 2 study
- September 14, 2024 (date) — Date of press release
FAQ
What specific type of cancer was the Phase 2 NuTide study focused on?
The Phase 2 NuTide study was focused on patients with biliary tract cancer.
What was the purpose of the press release filed on September 14, 2024?
The press release announced the presentation of final data from the Phase 2 NuTide study.
What form was used to file this announcement with the SEC?
The announcement was filed using a Form 6-K.
What is NuCana plc's principal executive office address?
NuCana plc's principal executive office is located at 3 Lochside Way, Edinburgh EH12 9DT, United Kingdom.
Does NuCana plc file annual reports under Form 20-F or Form 40-F?
NuCana plc files annual reports under Form 20-F.
Filing Stats: 330 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-09-16 06:05:26
Filing Documents
- d844681d6k.htm (6-K) — 9KB
- d844681dex991.htm (EX-99.1) — 12KB
- 0001193125-24-219152.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Donald Munoz Name: Donald Munoz Title: Chief Financial Officer Date: September 16, 2024